FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4376871783> ?p ?o ?g. }

• W4376871783 endingPage "e2313824" @default.
• W4376871783 startingPage "e2313824" @default.
• W4376871783 abstract "Importance Tyrosine kinase inhibitors (TKIs) have been recognized as the standard treatment for patients with non–small cell lung cancers (NSCLCs) and epidermal growth factor receptor (EGFR) sequence variation. Although TKIs have been reported to cause cardiotoxicity, they are widely administered owing to the high prevalence of EGFR sequence variation in Taiwan. Objective To compare the outcomes of death and major adverse cardiac and cerebrovascular events among patients with NSCLC who use and do not use TKIs in a national cohort. Design, Setting, and Participants Using data from the Taiwanese National Health Insurance Research Database and National Cancer Registry, patients treated for NSCLC from 2011 to 2018 were identified, and their outcomes were analyzed, including death and major adverse cardiac and cerebrovascular events (MACCEs; such as heart failure, acute myocardial infarction, and ischemic stroke) after adjusting for age, sex, cancer stage, comorbidities, anticancer therapies, and cardiovascular drugs. The median follow-up duration was 1.45 years. The analyses were performed from September 2022 to March 2023. Exposures TKIs. Main Outcomes and Measures Cox proportional hazards models were used to estimate death and MACCEs in patients treated with and without TKIs. Given that death may reduce the incidence of cardiovascular events, the competing risk method was used to calculate the MACCE risk after adjustment for all potential confounders. Results Overall, 24 129 patients treated with TKIs were matched with 24 129 patients who did not receive TKIs (24 215 [50.18%] were female; and the mean [SD] age was 66.93 [12.37] years). Compared with those not receiving TKIs, the TKI group presented with a significantly lower hazard ratio (HR) of all-cause death (adjusted HR, 0.76; 95% CI, 0.75-0.78; P &amp;lt; .001), and the reason for death was primarily cancer. In contrast, the HR of MACCEs significantly increased (subdistribution HR, 1.22; 95% CI, 1.16-1.29; P &amp;lt; .001) in the TKI group. Furthermore, afatinib use was associated with a significantly reduced risk of death among patients receiving various TKIs (adjusted HR, 0.90; 95% CI, 0.85-0.94; P &amp;lt; .001) compared with those receiving erlotinib and gefitinib, although the outcomes of MACCEs were similar between the 2 groups. Conclusions and Relevance In this cohort study of patients with NSCLC, TKI use was associated with reduced HRs of cancer-related death but increased HRs of MACCEs. These findings suggest the importance of close monitoring of cardiovascular problems in individuals receiving TKIs." @default.
• W4376871783 created "2023-05-18" @default.
• W4376871783 creator A5012822490 @default.
• W4376871783 creator A5013343509 @default.
• W4376871783 creator A5014480169 @default.
• W4376871783 creator A5021190064 @default.
• W4376871783 creator A5048306143 @default.
• W4376871783 date "2023-05-17" @default.
• W4376871783 modified "2023-09-26" @default.
• W4376871783 title "Assessment of Tyrosine Kinase Inhibitors and Survival and Cardiovascular Outcomes of Patients With Non–Small Cell Lung Cancer in Taiwan" @default.
• W4376871783 cites W1839859385 @default.
• W4376871783 cites W1935194167 @default.
• W4376871783 cites W1976427666 @default.
• W4376871783 cites W1986089152 @default.
• W4376871783 cites W1993397541 @default.
• W4376871783 cites W2036193982 @default.
• W4376871783 cites W2040299716 @default.
• W4376871783 cites W2042265219 @default.
• W4376871783 cites W2054841768 @default.
• W4376871783 cites W2086080786 @default.
• W4376871783 cites W2090941518 @default.
• W4376871783 cites W2096045098 @default.
• W4376871783 cites W2108554229 @default.
• W4376871783 cites W2118292700 @default.
• W4376871783 cites W2121279599 @default.
• W4376871783 cites W2133528707 @default.
• W4376871783 cites W2135412778 @default.
• W4376871783 cites W2157394282 @default.
• W4376871783 cites W2179573379 @default.
• W4376871783 cites W2206185841 @default.
• W4376871783 cites W2343881192 @default.
• W4376871783 cites W2414447865 @default.
• W4376871783 cites W2530508394 @default.
• W4376871783 cites W2587420003 @default.
• W4376871783 cites W2610486351 @default.
• W4376871783 cites W2626223149 @default.
• W4376871783 cites W2770828094 @default.
• W4376871783 cites W2773725797 @default.
• W4376871783 cites W2795353688 @default.
• W4376871783 cites W2996304730 @default.
• W4376871783 cites W3014286838 @default.
• W4376871783 cites W3020474870 @default.
• W4376871783 cites W3034752691 @default.
• W4376871783 cites W3095223882 @default.
• W4376871783 cites W3106861280 @default.
• W4376871783 cites W3116112050 @default.
• W4376871783 cites W3190216771 @default.
• W4376871783 cites W4233854028 @default.
• W4376871783 cites W4234236664 @default.
• W4376871783 cites W4238495530 @default.
• W4376871783 cites W4244740774 @default.
• W4376871783 cites W4280512457 @default.
• W4376871783 doi "https://doi.org/10.1001/jamanetworkopen.2023.13824" @default.
• W4376871783 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37195663" @default.
• W4376871783 hasPublicationYear "2023" @default.
• W4376871783 type Work @default.
• W4376871783 citedByCount "0" @default.
• W4376871783 crossrefType "journal-article" @default.
• W4376871783 hasAuthorship W4376871783A5012822490 @default.
• W4376871783 hasAuthorship W4376871783A5013343509 @default.
• W4376871783 hasAuthorship W4376871783A5014480169 @default.
• W4376871783 hasAuthorship W4376871783A5021190064 @default.
• W4376871783 hasAuthorship W4376871783A5048306143 @default.
• W4376871783 hasBestOaLocation W43768717831 @default.
• W4376871783 hasConcept C121608353 @default.
• W4376871783 hasConcept C126322002 @default.
• W4376871783 hasConcept C127413603 @default.
• W4376871783 hasConcept C143998085 @default.
• W4376871783 hasConcept C197934379 @default.
• W4376871783 hasConcept C207103383 @default.
• W4376871783 hasConcept C2776256026 @default.
• W4376871783 hasConcept C2776694085 @default.
• W4376871783 hasConcept C2778233292 @default.
• W4376871783 hasConcept C2778527826 @default.
• W4376871783 hasConcept C2780645631 @default.
• W4376871783 hasConcept C44249647 @default.
• W4376871783 hasConcept C500558357 @default.
• W4376871783 hasConcept C50382708 @default.
• W4376871783 hasConcept C71924100 @default.
• W4376871783 hasConcept C72563966 @default.
• W4376871783 hasConcept C77350462 @default.
• W4376871783 hasConcept C78519656 @default.
• W4376871783 hasConceptScore W4376871783C121608353 @default.
• W4376871783 hasConceptScore W4376871783C126322002 @default.
• W4376871783 hasConceptScore W4376871783C127413603 @default.
• W4376871783 hasConceptScore W4376871783C143998085 @default.
• W4376871783 hasConceptScore W4376871783C197934379 @default.
• W4376871783 hasConceptScore W4376871783C207103383 @default.
• W4376871783 hasConceptScore W4376871783C2776256026 @default.
• W4376871783 hasConceptScore W4376871783C2776694085 @default.
• W4376871783 hasConceptScore W4376871783C2778233292 @default.
• W4376871783 hasConceptScore W4376871783C2778527826 @default.
• W4376871783 hasConceptScore W4376871783C2780645631 @default.
• W4376871783 hasConceptScore W4376871783C44249647 @default.
• W4376871783 hasConceptScore W4376871783C500558357 @default.
• W4376871783 hasConceptScore W4376871783C50382708 @default.
• W4376871783 hasConceptScore W4376871783C71924100 @default.
• W4376871783 hasConceptScore W4376871783C72563966 @default.

• next